By Yasmeen Abutaleb and Michael Erman WASHINGTON, May 15 (Reuters) - The acting head of the U.S. Food and Drug Administration's drug center, Tracey Beth Hoeg, is expected to leave the agency just days after Commissioner Marty Makary resigned,

Stakeholders across the board are calling for a return to regular order at the FDA following the resignation of Commissioner Marty Makary, MD, MPH, who said he resigned in protest over the agency's decision to authorize flavored e-cigarettes.

Kyle Diamantas, FDA deputy commissioner for food, is serving as acting FDA commissioner in the wake of Dr. Marty Makary’s departure.

The Food and Drug Administration's top drug official is leaving in the latest shake-up at the powerful health agency. Dr. Tracy Beth Hoeg said in a social media post late Friday that she was

Several key allies of former Food and Drug Administration commissioner Marty Makary are departing their posts, according to people familiar with the matter, as the Trump administration attempts to create a clean slate at the agency.

Hundreds of biopharma leaders say Dr Richard Pazdur has the necessary qualities to lead the FDA amid a crisis of confidence.

Kyle Diamantas, who was elevated to FDA acting commissioner earlier this week, is telling anti-abortion groups he asked to be taken off a case defending Planned Parenthood due to moral objections.

Mifepristone is one of two drugs used in medication abortions, the most common method of ending a pregnancy. It has become a top target for abortion opponents, who are particularly frustrated because the FDA’s telehealth approval has made abortions easier to attain, including in states with abortion bans.